On December 4, 2025, Oncotelic Therapeutics, Inc. completed subscription agreements for 11 units, each consisting of a $25,000 note with 12% interest, convertible into shares at specified rates. The offering allows existing investors to convert EdgePoint shares into Oncotelic shares, enhancing its capital structure.